"Modernizing Drug Delivery"
A New Generation of Topical Targeted Drug Delivery Technology based on
Nanocrystals
About Socotra Pharmaceuticals
To preferentially accumulate in or around disease-target cells for the functional delivery of therapeutic agents, we will introduce highly improved dermal penetration of drugs by offering a new generation of Topical Targeted Drug Delivery based on Nanocrystal technology. Our technology will increase drug dissolution rate and deeper skin penetration. Socotra Pharmaceuticals provides effective and efficient drug delivery via a topical nanocrystal drug delivery method with the highest drug loading efficiency compared to other nano-based formulations and requires a low number of surfactants for stabilization resulting in a safer product for patients to use topically.
Our Vision
To drive technological innovations that combine pharmaceutical products and processes into systems, enhancing the integrity of parenteral drugs in a way that is far superior to anything that hasn't been achieved before.
Our Mission
To become a top-quality global healthcare provider that produces the world’s most advanced solutions, driven by an ethical and transparent mindset that can be guaranteed to patients.
Problems To Solve
The oral route is the most common for drug administration owing to its advantages, like non-invasiveness, patient compliance and convenience of drug administration. However, it suffers from several limitations of first-pass metabolism, poor stability in the gastric environment, etc.
Topical Nano drug delivery has poor long-term stability and high surfactant, which causes skin irritation. At the same time, applications of nanoparticles were very limited due to their low targeting efficiency and high toxicity levels—the severe toxic side effects of anti-cancer drugs to normal tissues due to the lack of tumour selectivity
Many anti-cancer drugs usually have strong side effects, the most common being nausea and vomiting. Most of the carriers available in the market are not suitable for cancer patients.
Drugs are loaded inside nanoparticles at preparation or attached to the surface via adsorption/ absorption methods. Drug loading efficiency is determined by both the carrier and drug properties, including molecular weight, the solubility of the drug in the carrier, the volumetric size of the carrier, and chemical interactions between the drug and the carrier.
Our Solution
Socotra Pharmaceuticals will use nanocrystals to overcome the problem of poor solubility and low bioavailability because of their specific structure. The Company will provide drug delivery systems with a mean particle size in the nanometer range, typically between 10–800 nm.
The Company’s nanocrystal-based formulation has the highest drug loading efficiency than other nano-based formulations. Also, it will provide effective results in minimal doses of the drugs and can cure the illness in less time.
Nanocrystals are drug crystals with sizes in the nanometer range stabilized or surrounded by a thin coating of in-lab synthesized bio-surfactants. The Company’s product has a low quantity of surfactant, making it a better and safer product.
The Company will provide targeted drug delivery utilizing nanotechnology-based topical gels which have no adverse effect on skin integrity. It has a system of specifying the drug directly into the targeted body area (organ, cellular, and subcellular level of specific tissue) to overcome the specific toxic effect of conventional drug delivery.
Our Products
Topical Nanocrystal Drug Delivery Gels (25mg & 50mg)
Drug-Loaded Nanocrystals (5gm & 25gm)
Nanocrystals are drug crystals with particle sizes ranging from dozens to a few hundred nanometers.
Advantages
Ultra-Durable and Stable Nanocrystals
Facilitated Drug Uptake
Enhanced Drug Permeation through Skin Barriers
Pleasant Feel
Well Suited for Anti-Cancer Drugs
Testimonials
Meet The Team
Ibrahim Ahmed Mohammed Hamiduddin
CEO
He is an accomplished pharmacist and a business executive with 26 years of experience. He had worked as Medical Rep, Scientific Office Manager, Regulatory Manager, Key Account Manager, Logistics Manager, Tender Manager, Co-Founder, CEO and Vice President. As Chief Executive Officer of Socotra Pharmaceuticals, Mr. Hamiduddin aims to utilize his excellent years of experience in the industry to ensure Socotra Pharmaceuticals’ success in its transition in the Canadian market.
Abdullah Hasan Abdullah Al-Sunaidar
COO
He is an intelligent, and accomplished business manager with 18 years of experience. He had worked as Internet Manager, Special Marketing Campaign Coordinator, Marketing and Development Director, Deputy Managing Director and General Manager. As Chief Operating Officer of Socotra Pharmaceuticals, Mr. Al-Sunaidar’s ability to optimize the company’s operating capabilities, and his varied experience in the industry will ensure that Socotra Pharmaceuticals continues to expand and surpass its short-and-long-term KPI’s in the Canadian market.
Emile Douaihy
CMO
He is an intelligent and soft-spoken management executive with a focus on fast-moving consumer goods (FMCG). He has 26 years of experience in the Sales and Marketing Industry. He had worked as Technical Sales Engineer, Promotions Manager, Regional Category Sales Manager, Category Marketing Manager, General Business Manager, Business Executive Manager and Business Executive Officer. As Chief Marketing Officer of Socotra Pharmaceuticals, Mr. Douaihy’s in-depth knowledge in areas of strategic marketing, outsourcing, and people relations will be vital for its ability to thrive in Canada.
Radwan Shaker AlZalak
CSO
He is a tactical master who places a strong emphasis on results and execution. He has 18 years of work experience. He had worked as National Sales Manager and Head of KAMs. As Chief Sales Officer of Socotra Pharmaceuticals, he will oversee the execution and planning of driving revenue growth and sales strategies. Mr. AlZalak’s ability to lead the company’s sales and to meet growth and sales revenue targets with his extensive leadership skills will ensure the success of Socotra Pharmaceuticals in the Canadian market.